Medizen Pharmaceutical Industries

What Medizen Pharmaceutical Industries does

Medizen Pharmaceutical Industries is an Egyptian branded-generic pharmaceutical manufacturer headquartered in Borg El Arab City (Alexandria industrial zone), founded in 2004 with commercial production beginning in June 2007 and fully acquired by Mega Misr (S.A.E) in September 2010. It operates a cGMP-compliant, ISO 9001:2008-certified facility producing tablets, powders & sachets, syrups, suspensions, semi-solids, hard gelatin capsules, and soft gelatin capsules across roughly 40-100 marketed products spanning antidiabetic, cardiology, dermatology, gastroenterology, neuropsychiatry, orthopedics, pediatrics, and uro-gynaecology, with 35 additional products in its registration pipeline.

The company's revenue model combines own-brand sales of branded generics (retailed in Egyptian Pounds at unit/pack level) with contract (toll) manufacturing for more than 40 third-party pharmaceutical clients including Pharmed, Liptis, Pharo Pharm, Al Andalous, AL Esraa, Magic Pharma, Trend Pharma, Royal Group, Napha, PharmaStar, and US-based Noveco Corp. Distribution flows through hospital supplies, government healthcare tenders, a domestic pharmacy network supported by five scientific offices (Cairo, Alexandria, El Mansoura, Tanta, Assiut), and export channels serving Yemen, South Sudan, Azerbaijan, Lebanon, and Palestine. Reported production capacity exceeds 20 million units per year.

Medizen's go-to-market relies on medical representatives, scientific symposia, and a corporate web presence targeting physicians, pharmacists, and hospitals. Its competitive positioning rests on niche therapeutic-area specialization (notably neuropsychiatry, cardiology, vascular surgery, and orthopedics), scale-driven cGMP manufacturing capacity, and toll-manufacturing relationships, with a workforce of 501-1,000 employees supporting a diversified but Egypt-centric operating model.

Name

Medizen Pharmaceutical Industries

Legal name

Medizen Pharmaceutical Industries

Website

https://medizenegypt.net

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Medizen Pharmaceutical Industries is an Egypt-based, Mega Misr-owned cGMP manufacturer of branded generic medicines in multiple dosage forms, serving domestic pharmacies, hospitals, government tenders, toll-manufacturing clients, and five export markets.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Toll manufacturing
• Branded generics
• Dosage forms

Headquarters

HQ city

`arab El-hiweitat

HQ country

Egypt

HQ region

Africa

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Pricing tiers

Distribution channels3 records

Marketing channels3 records

Core offering

Medizen Pharmaceutical Industries manufactures branded generic pharmaceutical products in multiple dosage forms including tablets, powders and sachets, syrup, suspension, semi-solids (creams, ointments, gels), and hard and soft gelatin capsules. The company operates a cGMP-compliant manufacturing facility in Borg El Arab, Alexandria, Egypt, producing over 100 products across therapeutic areas such as neuropsychiatry, cardiology, dermatology, gastroenterology, orthopedics, diabetology, pediatrics, and uro-gynaecology. It also provides toll manufacturing services for 40+ other pharmaceutical companies and exports to five countries.

Product overview

Medizen Pharmaceutical Industries is a branded generic pharmaceutical company manufacturing oral solids (tablets, sachets, powders, hard gelatin capsules), oral liquids (syrup, suspension), semisolid preparations (creams, ointments, gels), and soft gelatin capsules. The company produces over 40 marketed products across eight therapeutic areas including Antidiabetic (Diamedizen, Conida), Cardiology (Thormoxiban), Dermatology (Betapronate Plus, Isoromyderm, Smoothderm), Gastroenterology (Healioreptic, Diomacte, Prontomutim), Neuropsychiatry (Spiraquet, Night Calm, Pristimood, Arbateg), Orthopedics (Rheumatizen, Osteorine, Rhumaquick, Gincostazen), Pediatrics (Diomacte Suspension, Medmylezen, Four Vent), and Uro-gynaecology (Gynomonix). The product portfolio also includes Miscellaneous products (IMUXER, Tocozen, Golden Fer) and over 35 products in the pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

• Arbateg 200 mg Tablets Extended release film-coated tablets containing 200 mg carbamazepine for epilepsy treatment and trigeminal neuralgia.
• Arbateg Suspension 100 ml Suspension containing 100 mg carbamazepine per 5 ml for epilepsy and trigeminal neuralgia.
• Ascozental Combination of paracetamol 500 mg with vitamin C 300 mg for fever and pain relief, available in orange-flavored sachets.
• Betapronate Plus Cream Combination of betamethasone dipropionate 0.05% with clotrimazole 10 mg for inflammatory skin conditions with fungal infection.
• Bradozen 0.5 mg Lozenges Domiphen bromide lozenges for prevention and treatment of mouth and throat inflammation, priced at 15 L.E per 20 tablets.
• Diamedizen 30 mg MR Tablets Modified release gliclazide 30 mg tablets for type 2 diabetes mellitus with 24-hour glycemic control.
• Diamedizen 60 mg MR Tablets Modified release gliclazide 60 mg tablets for type 2 diabetes mellitus with single daily dose.
• Diclotazen Sachets 50 mg diclofenac potassium sachets for rapid anti-inflammatory and analgesic effect, particularly for dental pain.
• Diomacte Sachets 3 gm Dioctahedral smectite 3 gm sachets for treatment of acute and chronic diarrhea.
• Diomacte Suspension Dioctahedral smectite suspension for acute and chronic diarrhea, suitable for pregnant and lactating women.
• Gincostazen Capsules Combination of glucosamine and ginkgo-biloba for management of mild to moderate osteoarthritis, improving joint mobility.
• Golden Fer 100 mg Capsules

Quantifiable outcome

• Production capacity of more than 20 million units per year
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eleven partnerships are on record, tiered minor.

• Noveco Corp. (USA)minorChannel Partner/ Reseller/ DistributorOne of the toll manufacturing clients for Medizen, Noveco Corp. based in USA outsources pharmaceutical production to Medizen's manufacturing facilities.
• Liptis PharmaceuticalsminorChannel Partner/ Reseller/ DistributorToll manufacturing partner for Medizen Pharmaceutical Industries.
• Pharmed HealthcareminorChannel Partner/ Reseller/ DistributorToll manufacturing partner for Medizen Pharmaceutical Industries.
• Al Andalous PharmaceuticalsminorChannel Partner/ Reseller/ DistributorToll manufacturing partner for Medizen Pharmaceutical Industries.
• AL Esraa PharmaceuticalsminorChannel Partner/ Reseller/ DistributorToll manufacturing partner for Medizen Pharmaceutical Industries.
• Magic PharmaminorChannel Partner/ Reseller/ DistributorToll manufacturing partner for Medizen Pharmaceutical Industries.
• Trend PharmaminorChannel Partner/ Reseller/ DistributorToll manufacturing partner for Medizen Pharmaceutical Industries.
• Royal Group (Pharmaceuticals)minorChannel Partner/ Reseller/ DistributorToll manufacturing partner for Medizen Pharmaceutical Industries.
• Napha PharmaminorChannel Partner/ Reseller/ DistributorToll manufacturing partner for Medizen Pharmaceutical Industries.
• PharmaStarminorChannel Partner/ Reseller/ DistributorToll manufacturing partner for Medizen Pharmaceutical Industries.
• Pharo PharmminorChannel Partner/ Reseller/ DistributorToll manufacturing partner for Medizen Pharmaceutical Industries.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Aurobindo Pharma: Large Indian generic manufacturer with significant MEA, Africa and CIS distribution. Represents the global generics competitive pressure Medizen faces in export and tender markets, with a much broader scale and API integration.
• Cipla: Indian-headquartered global generics powerhouse with strong MEA presence including South Africa and Egypt. Competes with Medizen's products in tender markets and is increasingly active in the same MEA geographies Medizen exports to.

Direct peers

• Mepaco (Arab Pharmaceuticals & Chemicals Industries): Egyptian pharmaceutical manufacturer with similar branded-generic portfolio and toll-manufacturing capabilities. Comparable cGMP facilities, dosage-form breadth and target market across MEA.
• Eva Pharma: Major Egyptian branded-generic manufacturer covering multiple therapeutic areas including neuropsychiatry, cardiology and dermatology. Closely comparable to Medizen in portfolio breadth, dosage-form coverage and toll-manufacturing exposure.
• Pharco Pharmaceuticals: Largest Egyptian pharmaceutical company and a regional branded-generic exporter. Comparable business model with broad therapeutic coverage, cGMP manufacturing, government tender participation and exports to MEA markets.
• EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest Egyptian pharmaceutical manufacturers producing generics in tablets, capsules, syrups, suspensions and semi-solids. Direct competitor to Medizen across branded generics, government tenders and toll manufacturing within the Egyptian market.
• Amoun Pharmaceutical: Leading Egyptian pharma manufacturer producing branded generics across multiple therapeutic areas. Directly comparable on dosage forms (tablets, capsules, syrups), Egyptian market positioning and export activity.

Regional players

• Julphar (Gulf Pharmaceutical Industries): UAE-based generics manufacturer exporting across the MENA region. Comparable on dosage-form coverage, branded-generic portfolio and regional export strategy, though Medizen serves Egypt domestically while Julphar serves Gulf markets.
• Hikma Pharmaceuticals: Jordan-headquartered MEA-focused generics and specialty pharma company with manufacturing in Egypt and the broader region. Comparable therapeutic breadth, branded-generic positioning and MEA export reach, though larger and more geographically diversified.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Saudi Arabian pharmaceutical manufacturer producing branded generics for the GCC and MEA. Comparable on dosage-form coverage and government tender exposure, though operating in a different primary geography than Medizen.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/medizenpharmaceutical
• LinkedInlinkedin.com/company/medizen-pharmaceutical-industries

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medizen Pharmaceutical Industries